The company reported net income of $121.4 million, or $4.25 per share, showing a sharp increase from the $90.3 million, or $3.10 per share, recorded during the same period last year. Revenue climbed 17% to reach $707.3 million, surpassing the $689.5 million consensus estimate from analysts polled by FactSet.

Looking ahead, Medpace issued bullish guidance for fiscal 2026. The firm projects annual revenue between $2.81 billion and $2.89 billion, with net income expected to land between $494 million and $514 million. These figures sit ahead of current analyst projections of $2.77 billion in revenue and $493.2 million in net income, reflecting sustained momentum for the research organization.